Evogene (NASDAQ:EVGN) Announces Quarterly Earnings Results, Misses Expectations By $0.94 EPS

Evogene (NASDAQ:EVGN) released its quarterly earnings data on Thursday. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.94), Zacks reports. The firm had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%.

Evogene Price Performance

Shares of EVGN traded up $0.33 during trading hours on Friday, hitting $3.88. The stock had a trading volume of 75,417 shares, compared to its average volume of 16,585. Evogene has a 12 month low of $3.45 and a 12 month high of $10.40. The stock has a fifty day moving average price of $5.35 and a 200 day moving average price of $6.79. The firm has a market capitalization of $159.92 million, a PE ratio of -8.43 and a beta of 1.40.

Analyst Ratings Changes

Several brokerages recently weighed in on EVGN. Lake Street Capital reduced their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday. StockNews.com assumed coverage on shares of Evogene in a research note on Thursday. They set a “sell” rating on the stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.